[Prognostic factors in metastasizing melanoma]

Area of Science:

• Oncology
• Clinical Cancer Research

Background:

• Advanced malignant melanoma presents a significant clinical challenge.
• Chemotherapy is a standard treatment, with immunotherapy explored as an adjunct.

Purpose of the Study:

• To evaluate the prognostic significance of clinical parameters in advanced malignant melanoma.
• To assess the efficacy of chemo-immunotherapy versus chemotherapy alone.

Main Methods:

• Analysis of 133 patients with advanced malignant melanoma from two Swiss Group for Clinical Cancer Research (SAKK) studies.
• Comparison of poly chemotherapy alone versus poly chemotherapy with non-specific immunotherapy (MER).

Main Results:

• Combined chemo-immunotherapy yielded inferior results compared to chemotherapy alone.
• Patients achieving partial remission had significantly longer survival than those with progressive disease.
• Performance status, metastasis sites, primary tumor location, and sex were significant prognostic indicators.

Conclusions:

• Chemo-immunotherapy with MER was not superior to chemotherapy alone in this patient cohort.
• Identified prognostic factors can aid in stratifying patients for future clinical trials.